{
    "clinical_study": {
        "@rank": "38498", 
        "acronym": "SORINT", 
        "arm_group": {
            "arm_group_label": "Group 1"
        }, 
        "brief_summary": {
            "textblock": "The study aims to investigate patient characteristics of intermediate stage hepatocellular\n      carcinoma patients treated with Nexavar and their distribution to different treatment groups\n      as well as determining efficacy and safety parameters."
        }, 
        "brief_title": "Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety", 
        "completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma, Hepatocellular", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with a diagnosis of unresectable intermediate stage hepatocellular carcinoma\n             (BCLC-B) for whom the decision has been taken by the investigator to prescribe\n             Nexavar (the BCLC intermediate stage (BCLC-B) consists of Child-Pugh A and B patients\n             with large/multifocal HCC who do not have cancer related symptoms, macrovascular\n             invasion or extrahepatic spread).\n\n        Exclusion Criteria:\n\n        -  Prior targeted therapy for hepatocellular carcinoma."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The study population will consist of patients with intermediate stage hepatocellular\n        carcinoma (BCLC-B) treated with Nexavar according to the local summary of product\n        characteristics. Participants will be recruited from oncological and gastroenterological\n        clinics and practices throughout Germany.\n\n        In this non-interventional observational study, the decision on the duration and dosage of\n        treatment is solely at the discretion of the attending physician.\n\n        The medication is prescribed at regular visits to the investigator's office. Commercially\n        available product will be used to treat the patients."
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01908322", 
            "org_study_id": "16628"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Patients will be followed-up from start of Nexavar therapy until death or drop out due to any reason or end of study", 
            "intervention_name": "Sorafenib (Nexavar, BAY43-9006)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Sorafenib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hepatocellular carcinoma", 
            "Intermediate stage", 
            "Observational study"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Germany"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "SORINT - SORafenib for Treatment of Patients With INTermediate Stage Hepatocellular Carcinoma", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Distribution of intermediate stage hepatocellular carcinoma (HCC) patients treated with Nexavar to different treatment groups will be evaluated by the relative frequency of patients in each treatment group.", 
                "safety_issue": "No", 
                "time_frame": "up to 54 months"
            }, 
            {
                "measure": "Characteristics of patients with intermediate stage HCC (BCLC-B) treated with Nexavar will be determined by evaluating demographic data, medical history, previous treatment of HCC, specific concomitant conditions (amongst others).", 
                "safety_issue": "No", 
                "time_frame": "up to 54 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01908322"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall Survival is measured as the time interval from start of Nexavar therapy to the date of death, due to any reason.", 
                "safety_issue": "No", 
                "time_frame": "up to 54 months"
            }, 
            {
                "measure": "Time to progression is defined as the time interval from start of Nexavar therapy to the date of diagnosed progression.", 
                "safety_issue": "No", 
                "time_frame": "up to 54 months"
            }, 
            {
                "measure": "Progression free survival is measured as the time interval from the start of Nexavar treatment to diagnosed (radiological or clinical) progression or death, whichever comes first.", 
                "safety_issue": "No", 
                "time_frame": "up to 54 months"
            }, 
            {
                "measure": "Time to treatment failure is defined as the time interval from start of Nexavar therapy to the date of diagnosed progression or permanent discontinuation due to toxicity.", 
                "safety_issue": "No", 
                "time_frame": "up to 54 months"
            }, 
            {
                "measure": "Duration of Nexavar treatment is measured as the time interval from start of Nexavar therapy to the date of permanent discontinuation of Nexavar therapy (regardless of the reason for discontinuation).", 
                "safety_issue": "No", 
                "time_frame": "up to 54 months"
            }, 
            {
                "measure": "Tumor status at different visits will be evaluated according to radiological or clinical evaluation. The best overall response will be analyzed providing absolute and relative frequencies of the tumor status categories.", 
                "safety_issue": "No", 
                "time_frame": "up to 54 months"
            }, 
            {
                "measure": "Further possible prognostic factors will be evaluated.", 
                "safety_issue": "No", 
                "time_frame": "up to 54 months"
            }, 
            {
                "measure": "Safety variables will be summarized using descriptive statistics based on adverse events collection.", 
                "safety_issue": "Yes", 
                "time_frame": "up to 54 months"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}